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Abstract
Background: Homelessness increases the risk of tuberculosis (TB) disease and latent TB infection (LTBI), but persons
experiencing homelessness often lack access to testing and treatment. We assessed the yield of TB testing and
linkage to care for programs targeting homeless populations in the United States.
Methods: We conducted a comprehensive search of peer-reviewed and grey literature, adapting Cochrane
systematic review methods. Two reviewers independently assessed study eligibility and abstracted key data on the
testing to care cascade: number of persons reached, recruited for testing, tested for LTBI, with valid test results,
referred to follow-up care, and initiating care. We used random effects to calculate pooled proportions and 95%
confidence intervals (CI) of persons retained in each step via inverse-variance weighted meta-analysis, and
cumulative proportions as products of adjacent step proportions.
Results: We identified 23 studies published between 1986 and 2014, conducted in 12 states and 15 cities. Among
studies using tuberculin skin tests (TST) we found that 93.7% (CI 72.4-100%) of persons reached were recruited, 97.
9% (89.3-100%) of those recruited had tests placed, 85.5% (78.6-91.3%) of those with tests placed returned for
reading, 99.9% (99.6-100%) of those with tests read had valid results, and 24.7% (21.0-28.5%) with valid results
tested positive. All persons testing positive were referred to follow-up care, and 99.8% attended at least one session
of follow-up care. Heterogeneity was high for most pooled proportions. For a hypothetical cohort of 1000 persons
experiencing homelessness reached by a targeted testing program using TST, an estimated 917 were tested, 194
were positive, and all of these initiated follow-up care.
Conclusions: Targeted TB testing of persons experiencing homelessness appears effective in detecting LTBI and
connecting persons to care and potential treatment. Future evaluations should assess diagnostic use of interferon
gamma release assays and completion of treatment, and costs of testing and treatment.
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Background
Nearly 600,000 people in the United States (US) experi-
enced homelessness on any one night in 2015, whether
they slept in homeless shelters or in other locations [1].
Homelessness is a high risk factor for tuberculosis
disease (TB) and latent TB infection (LTBI) [2] and per-
sons experiencing homelessness are at an estimated 10
times greater risk of being diagnosed with TB disease
than the general population [3]. More than 5% of TB
cases reported to the National TB Surveillance System
have experienced homelessness in the preceding year
[4]. Homelessness increases risk of TB due to exposure
in crowded shelters, and its association with substance
use, and HIV infection, which lowers immunity [2].
It is critical to diagnose LTBI in patients in order to
provide treatment, prevent disease progression, and sub-
sequently prevent TB transmission should progression
to TB disease occur. Early TB infection diagnosis in
homeless populations can be challenging because many
have barriers to accessing health care, including lack of
health insurance, difficulty paying for care, lack of trans-
portation, and lack of information needed to access care
[2, 5, 6]. Linking homeless persons diagnosed with LTBI
to further follow-up and assessment for treatment is
critical for their health and for TB disease elimination
efforts. Targeted tuberculosis testing programs (TTTs)
test persons from high risk populations, such as persons
experiencing homelessness or persons born in high inci-
dence countries, for LTBI. This is done using one of two
test types, the tuberculin skin test (TST) or an interferon
gamma release assay (IGRA). There are advantages and
disadvantages to each test type in homeless populations.
TSTs require that persons who have tests placed, return
within 48 to 72 h to have the test read. Coming back to
the test site within a fixed time period can be challen-
ging for persons experiencing homelessness who may re-
locate frequently, are financially stressed, and commonly
suffer from mental health disorders. In contrast, IGRAs
are performed in a lab, and do not require any contact
with the person being tested, aside from the initial blood
draw, to obtain valid test results. However, persons who
test positive must be located in order to inform them of
their test results and coordinate follow-up care, which
can be very challenging for persons without fixed
addresses or contact information, whereas with TSTs,
positive results can be communicated and follow-up
referrals given immediately once the person returns for
TST reading.
Strategies for increasing targeted testing for LTBI and
linkage to care of homeless populations may help to
decrease TB incidence. In this review, we seek to assess
the yield of such programs by assessing the proportion
of persons experiencing homelessness who are retained
in each step of the TTT cascade.
Methods
Our search, screening, study selection and analysis
methods are based on those of the Cochrane Collabor-
ation, as presented in the Cochrane Handbook for
Systematic Reviews of Interventions [7]. We followed
the Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) guidance [8] in reporting
our review. Our protocol is registered on PROSPERO
(CRD42016039432) [9].
Eligibility criteria
We included studies reporting the results of TTT pro-
grams in adolescents and adults experiencing homeless-
ness in the US. Programs needed to target homeless
populations specifically, but could include a minority of
participants who were stably housed. We defined study
populations as homeless if participants were recruited
from homeless shelters, health care clinics for homeless
populations, or other service agencies primarily serving
homeless clientele. We also included studies that de-
scribed the study populations as homeless or used related
terms such as unhoused, unstably housed, itinerant, street
youth or other such terms (see Additional file 1).
Eligible studies must have used a biological test such
as tuberculin skin test (TST) or interferon gamma re-
lease assay (IGRA) to ascertain LTBI. Eligible studies
needed to report, at minimum, the numbers of partici-
pants with valid LTBI test results and numbers of those
testing positive. We excluded studies that used only self-
report to assess LTBI, as well as contact investigations,
studies where stored specimens were tested for evidence
of infection, and studies reporting testing results
unlinked to patient identity. We excluded studies that
tested participants only for active TB disease (i.e., not
LTBI), such as those reporting only data from chest ra-
diographs or sputum testing. We also excluded studies
that primarily focused on populations aged 14 or under.
We did not have any eligibility restrictions based on pub-
lication status, study design, or language of publication.
Single arm and multi-arm studies were eligible. Studies
from peer reviewed literature or from conference abstracts
and other grey literature were eligible for inclusion.
Search, screening, and study selection
We developed a comprehensive search strategy that in-
cluded multiple variations and synonyms of relevant TB
and “homelessness” terms as well as National Library of
Medicine Medical Subject Heading (MeSH) terms and
Embase “Emtree” indexing terms. Because our original
conception of this review also included studies address-
ing HIV, hepatitis B and hepatitis C in homeless popula-
tions, our strategy includes terms relevant to those
conditions. We subsequently decided to report our re-
view of studies concerned with these blood-borne
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infections in a separate manuscript [data analysis report
provided to the US Centers for Disease Control and
Prevention (CDC) on September 21, 2016]. In this
review we focus only on TB studies.
We searched PubMed, Embase, Web of Science and
the Cochrane Central Register of Controlled Trials, from
earliest records to June 13, 2016. Additional file 1
provides our search strategies. We additionally hand-
searched CDC’s TB Notes Newsletters and available
abstracts from the National TB Controllers’ Association
National TB Conferences and searched abstracts from
the American Public Health Association’s annual confer-
ences. We reviewed the bibliographies of our included
studies as well as references cited in a previous system-
atic review which examined the prevalence of TB disease
in homeless populations [10].
Two persons, working independently, applied eligibil-
ity criteria to titles and abstracts of all studies captured
in the searches and each identified a selection of
potentially-eligible studies. They then compared their
respective selections and reached consensus about
potential eligibility. A third author stood ready to serve
as neutral arbiter in case consensus was not reached, but
this was never necessary. Two persons then reviewed
full-text articles of records deemed potentially eligible
and in an identical process, made final decisions about
study eligibility.
Elements of the testing and care Cascade
Outputs of interest in the TTT cascade were the number
of participants who:
1. Were Reached: contacted and invited to participate
in the testing program.
2. Were Recruited: agreed to participate in the testing
program.
3. Were Tested: had TSTs placed or blood drawn for
IGRA testing.
4. Had a TST read: had a TST evaluated. This step
does not apply to studies that used IGRA.
5. Had valid results: with a clear positive or negative
test result given to testing program staff. This
excludes participants with inconclusive IGRA or
TST results.
6. Tested positive: tested positive for TB infection. We
used the respective studies’ definitions of positive
test results.
7. Were referred for follow-up: provided with information or
an appointment to receive further evaluation of positive test
results and treatment, if appropriate.
8. Attended follow-up: attended at least one session
for evaluation of a positive test and/or for treatment
services. This includes participants who were
evaluated for LTBI treatment, but deemed to be
unsuitable candidates for therapy.
We also extracted the number of active cases that
were diagnosed upon follow-up of positive TSTs or
IGRAs, but did not consider it part of the “cascade” be-
cause our cascade ends with attendance for follow-up
care, which must occur prior to TB disease or LTBI
diagnosis. As this review focuses on testing for LTBI,
cases of TB disease diagnosed by chest X-ray or sputum
sample done in the absence of a positive TST or IGRA,
were not extracted.
Data extraction
One person extracted key data into a pre-piloted and stan-
dardized data extraction spreadsheet (Additional file 2). A
second person independently extracted data from the
TTT care cascade, blinded to the first author’s extraction,
and checked the remainder of the first extraction for ac-
curacy. These independent extractions were compared
and reconciled via consensus or by decision of the arbiter.
Risk of bias assessment
We did not formally assess risk of bias in the individual
studies since existing standard instruments for assessing
bias risk for intervention efficacy, prevalence, and other
epidemiologic studies were not applicable to studies
reporting yield of screening programs.
Statistical analysis and data synthesis
All analyses were conducted using Stata version 14.
Proportions of persons proceeding from one step in the
testing and linkage to care cascade to subsequent steps
and associated 95% confidence intervals (CIs) were cal-
culated using the Wald method. As we wanted to assess
the performance of these programs in detecting new
cases of LTBI, when studies reported testing persons
with a known history of TB infection or TB disease, we
subtracted their number from all cascade steps except
the number reached. If two or more studies reported
data for the same proportion, pooled proportions were
calculated using inverse-variance random effects meta-
analysis. The Freeman-Tukey double arcsine transform-
ation was used to normalize individual study proportions
prior to pooling. Where data existed, we also analyzed
proportions stratified by recruitment method (health-
care facility based recruitment vs. recruitment from
other service agencies).
We calculated pooled cumulative proportions for each
step in the cascade for the subset of studies that used
TST for testing. Cumulative proportions were products
of adjacent-step pooled proportions. The cumulative
proportion tested of those reached was equal to the
product of the proportion recruited of those reached
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and the proportion tested of those recruited. The cumu-
lative proportion with valid test results of those reached
was equal to the product of the cumulative proportion
tested of those reached and the proportion with valid
test results of those tested. Each subsequent cumulative
proportion was the product of a single step proportion
and the cumulative proportion that immediately pro-
ceeded it. We also calculated cumulative proportions
stratified by test type, using test specific values for the
proportion with valid test results of those tested and the
proportion testing positive of those with valid test
results. Confidence intervals for cumulative proportions
were calculated using a simulation method. Each pooled
proportion and confidence limit closest to 0.5 were nor-
malized using the Freeman-Tukey double arcsine trans-
formation, with a sample size equal to the harmonic
mean of the individual study sample sizes and the num-
ber of successes equal to the product of the pooled pro-
portion and the harmonic mean. For each pooled
proportion, we took 50,000 draws from a normal distri-
bution with a mean equal to the transformed pooled
proportion and a standard deviation equal to the abso-
lute value of the difference between the transformed
mean and the transformed confidence limit divided by 1.
96. Draws less than the transformed value of zero were
replaced with the transformed value of zero, and draws
greater than the transformed value of one were replaced
with the transformed value of one. Draws were then
reverse transformed into proportions to build probability
distributions for each pooled proportions. Draws for
each proportion were then multiplied with draws from
the next proportion in the cascade in a sequential man-
ner, and the 95% confidence intervals were taken from
the 2.5th and 97.5th percentile of the resulting product
distributions.
The time trend for the proportions testing positive of
persons with valid results for studies using TST that
included dates of data collection was analyzed using the
Spearman’s rank correlation coefficient.
Results
Identified studies
From a total of 3566 peer-reviewed citations identified
through article databases and tracking of cited references
of included studies in Scopus, 40 met inclusion criteria
for either the TB or the blood-borne disease review, 21
of these reported outcomes of TB testing. Figure 1
details this process, and Additional file 3 lists reasons for
exclusion after full-text review. In addition to 21 indexed
publications, we found one eligible study cited in CDC’s
peer-reviewed newsletter “TB Notes” and one confer-
ence abstract via our grey literature search. Descriptions
of the included studies are in Table 1. Studies were con-
ducted in 12 states and at least 15 cities (including six in
New York City). With the possible exception of one
study conducted in an unnamed county in Indiana [11],
all studies took place in urban areas. Studies were
published or presented between 1986 and 2014, with
data collection reported to be between 1982 and 2009.
Of 15 studies [12–26] that reported gender distribution,
8 [12, 14, 17, 18, 21, 24–26] had exclusively male study
populations, the remainder had between 4% and 22%
female study populations. In most studies that reported
race, the majority of the populations were African
American. Two studies used IGRA [27, 28], and one
study used a combination of TST and IGRA [11] for
testing, the remainder relied exclusively on TST.
Test and linkage to care cascade – TST studies
Twenty studies [12–26, 29–34] used TST for testing.
Additional file 4: Table S1 reports proportions of per-
sons proceeding from each cascade step to subsequent
steps, and the number of studies contributing data on
each proportion. Of persons reached, 93.7% (95% CI 72.
4 to 100%) were recruited; of persons recruited, 97.9%
(89.3 to 100%) had tests placed; of those with tests
placed, 85.5% (78.6 to 91.3%) returned to have tests read;
of those with tests read, 99.9% (99.6 to 100%) had valid
test results; and of those with valid test results, 24.7%
(21.0 to 28.5%) tested positive. Of four studies [12, 14,
19, 26] that reported number given a referral for follow-
up, all persons who tested positive were referred, and 99.
8% of persons who agreed to be referred to care
attended at least once. Among the eleven studies [12, 14,
15, 19, 21, 23, 25, 29, 31–33] that reported number of
TB disease cases diagnosed among persons tested for TB
infection, 1.2% (0.0 to 3.4%) of persons testing positive
were diagnosed with TB disease. The proportion of vari-
ability in the effect estimates that is due to heterogeneity
(I2) was greater than 75% for all proportions where I2
was calculable, except the proportion referred to
treatment of those testing positive (I2 = 0), for which all
study estimates were 100%, and proportion attending
treatment of those referred to treatment (I2 = 59.1%).
Adjacent step and cumulative proportions in the testing
and linkage to care cascade are shown in Fig. 2. For a
hypothetical cohort of 1000 homeless persons reached in
studies using TST, we estimate that 784 (95% CI 585 to
880) would have valid test results, 194 would test positive
(140 to 234), all 194 (139 to 234) would be referred to
follow-up and 193 (134 to 231) would attend follow-up.
The proportions testing positive declined over time
(Spearman’s ρ = − 0.57, p = 0.046). Figure 3 displays this
finding graphically.
Testing and linkage to care cascade – IGRA studies
Two studies that relied exclusively on IGRA [27, 28],
recruited participants from health care facilities in San
Parriott et al. BMC Public Health  (2018) 18:485 Page 4 of 11
Francisco. Neither study reported numbers reached, re-
cruited, or referred to follow-up. The pooled proportion
of persons with valid test results of those tested was 97.
0% (95% CI 96.8 to 97.3%) and the pooled proportion
testing positive of those with valid test results was 8.9%
(8.4 to 9.4%). One of these studies reported that 274
(67%) of 411 persons testing positive attended follow-up
care [27].
One study [11] relied on a combination of TST and
IGRA for testing without stratifying results by test type,
but appears to have used mostly IGRA. In this study, of
1421 persons with valid test results, 185 (13%) tested
positive, and 158 attended follow-up care.
Recruitment type sub-analysis
Table 2 displays pooled proportions stratified by recruit-
ment type for studies using TST for testing. Persons
recruited at health care facilities (usually clinics for
homeless persons) were retained at higher proportions
for the first three steps of the cascade than persons
recruited from other types of facilities. This difference is
only statistically significant at α = 0.05 for recruited of
reached.
Discussion
This systematic review is, to the best of our knowledge,
the first systematic review analyzing the performance of
Fig. 1 PRISMA flowchart. Process of identification and screening of citations from article databases, targeted testing and linkage to care studies
among homeless populations in the United States
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Table 1 Characteristics of 23 TB targeted testing and linkage to care studies among homeless populations in the United States
Author and
year
Data collection years City/county, State Target population Recruitment method Number of valid
test results
Barry 1986 [15] 1984 Boston, Massachusetts Homeless adults Shelter-based 187
McAdam 1990 [15] 1982-1988 New York, New York Homeless adults Shelter-based 1508
Torres 1990 [16] 1986-1989 New York, New York Individuals staying at a
“Gay Mens” Shelter on
Ward Island
Shelter, and healthcare
facility-based
94
Nolan 1991 [17] 1985 Seattle, Washington Homeless men Shelter-based 93
Neims 1992 [18] Not reported Baltimore, Maryland Individuals who spent at
least one night in a
homeless shelter in the
previous year.
Shelter, healthcare facility,
and other service-based
57
Paul 1993 [20] 1990 New York, New York Homeless men Shelter-based 98
Gelberg 1997 [21] 1991 or 1992-
not reported
Los Angeles,
California
Homeless adults Participants were recruited
from a separate longitudinal
cohort of homeless persons
conducted by the RAND
Corporation; the RAND
cohort was recruited using a
combination of shelter-based,
meal program-based,
and street-based recruitment
260
Morrow 1997 [22] Not reported Yonkers, New York Underserved men and
women using the shelter’s
services (food, clinic,
sleeping there)
Shelter-based 95
Sakai 1998 [19] 1996 New Orleans,
Louisiana
Homeless men Shelter-based 105
Bock 1999 [23] 1994-1996 Atlanta, Georgia “High- risk” inner city residents Healthcare facility-based 2002
Griffin 1999 [24] 1997-1998 Kansasa City, Missouri Homeless adults Shelter-based 654
Kimerling 1999 [25] 1996-1996 Birmingham, Alabama Homeless adults Shelter-based 21
Falchook 2000 [26] 1998-1999 New Orleans,
Louisiana
Homeless adults Shelter-based 54
Kong 2002 [27] 1995-1998 Denver, Colorado Residents of communal
shelters and residential
drug and alcohol treatment
programs
Shelter and other
service-based
10,207
Cheung 2002 [28] 1995-2000 Menlo Park, California VA-eligible homeless adults Healthcare facility-based 829
Saez 2002 [32] 1990-1992 New York City, New
York
Mentally ill homeless men Shelter and healthcare
facility-based
75
Forman 2003 [29] 2001 Anchorage, Alaska Homeless adults Shelter-based 47
Valencia 2004 [30] Not reported New York, New York Mentally ill homeless men Shelter-based 173
Dewan 2006 [12] 2003-2005 San Francisco,
California
Homeless adults Healthcare facility-based 2559
Lashley 2007 [31] 2005-2007 Baltimore, Maryland Homeless adults in or recently
graduated from a residential
addictions recovery program
Shelter-based 282
McAdam 2009 [33] 1992-2006 New York, New York Homeless persons attending
shelters and drop-in facilities
Shelter and other
service-based
21,028
Alexander 2011 [11] 2009-2011 County not reported,
Indiana
Homeless adults Shelter-based with street
outreach component: health
fairs and another event offering
legal, social and health services
to the homeless.
1421
Higashi 2014 [13] 2005-2009 San Francisco,
California
Homeless adults Healthcare facility-based 10,935
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programs testing for LTBI, rather than TB disease, in
homeless persons in the United States. We generally
found promising yields of persons tested and LTBI
detected. Compliance with testing was generally high,
and even though some persons tested with TST did not
return to have their tests read, we estimate that nearly
four out of five persons reached by these targeted testing
programs will obtain valid test results. More than 99% of
persons who tested positive for infection were success-
fully referred to and attended at least one session of
follow-up care. The proportion of persons testing TST
positive of those with valid results (25%) is higher than
would be expected among the general public [35]. In
studies using TST, nearly 15% of persons who had tests
placed did not return at the appropriate time to have
them read. Because IGRA does not require a return visit
to obtain test results, it may be possible to communicate
test results when the patient makes contact with the
testing organization at a later date, or over the phone or
through mail for persons who have means to receive
these types of communications, thus it is possible that
use of IGRA will reduce the number of persons who re-
main unaware of their infection. Although the primary
goal of these testing programs was to detect cases of
LTBI, we found that an average of 1.2% of persons who
tested positive were found to have TB disease on follow-
up evaluation. Thus, LTBI targeted testing programs in
homeless populations may also aid in the detection of
cases of TB disease, which may lead to earlier diagnosis
and less time spent with a transmissible infection.
We elected not to include data on treatment initiation
and adherence as outcomes in this review, as we anticipated
that most studies that included treatment outcomes would
start with persons diagnosed with LTBI, rather than follow-
ing a cohort through testing and diagnosis. Current recom-
mended LTBI treatment options for most adults include
shorter course regimens such as 4 months of daily rifampin,
or 12 weekly doses (3 months) of isoniazid with rifapentine
by directly observed therapy (DOT), in addition to the
standard treatment of 9 months of daily or intermittent (by
DOT) isoniazid [36]. Randomized controlled trials [37, 38],
a meta-analysis [39], and an observational study [40]
suggest that shorter course LTBI treatment regimens are
associated with significantly higher treatment completion
rates, even among persons experiencing homelessness and
other marginalized groups. A systematic review of adher-
ence to newer short-course regimens in persons experien-
cing homelessness would be a valuable companion piece to
this review, and allow assessment of the entire LTBI
continuum of care in this high risk population.
Fig. 2 Cumulative proportion of homeless populations retained in each cascade step. TB targeted testing and linkage to care in the United
States. TST-based studies only. Proportions retained from each step to the next are displayed in the table below
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Limitations
Meta-analyses often include a formal assessment of
study bias. The Cochrane recommended tool for bias as-
sessment was developed for the purpose of evaluating
studies that compare an intervention with a control con-
dition. This tool was considered inappropriate for the
evaluation of this study because this analysis does not
seek to compare one condition to another. We are
unaware of any widely used and well accepted instru-
ment for the evaluation of biases in studies that seek to
estimate the yield of disease screening programs, there-
fore we did not conduct a formal bias assessment of in-
dividual studies. However, we can speculate on the types
of biases that may have affected our results. A likely
major source of bias is publication bias. The results of
TTT programs for homeless persons are rarely
Fig. 3 Proportions testing positive of those with valid results by year in homeless populations. TB targeted testing and linkage to care in the
United States. TST-based studies only. Midpoint year of data collection was used when data collection accrued over multiple years
Table 2 Proportions for select steps in TB targeted testing cascade among homeless persons, by recruitment method
Cascade Step Number of
studies*
N Proportion 95% CI Number of
studies*
N Proportion 95% CI P value for difference
between recruitment
types
Healthcare facility based Other service based**
Recruited of reached 1 829 100% 99.5 to 100% 1 750 78.1% 75.0 to 80.9% < 0.001
Tests placed of recruited 2 923 100% 99.9 to 100% 5 2775 95.2% 80.8 to 100% 0.081
Valid results of tests placed 4 3926 93.9% 65.1 to 91.1% 6 26,839 78.6% 70.8 to 85.5% 0.247
Positive of valid results 4 3000 33.6% 18.0 to 51.2% 11 33,661 23.5% 19.1 to 28.3% 0.249
Referred to follow-up of
positive
1 33 100% 89.6 to 100% 2 113 100% 98.3 to 100% 1.000
Attended follow-up of
referred
1 33 100% 89.6 to 100% 2 113 100% 98.3 to 100% 1.000
*Not all studies reported data on all cascade steps
**Other service based recruitment includes recruitment from shelters, single room occupancy hotels, drop-in/day centers, substance abuse treatment facilities,
meal programs, and other agencies that provide services to a primarily homeless or very low income clientele
Parriott et al. BMC Public Health  (2018) 18:485 Page 8 of 11
published because assessments done by busy public
health workers are intended only to inform the program.
It is possible programs that publish or otherwise dissem-
inate their results differ from programs that do not. For
example, programs may publish about exceptionally
successful programs, or conversely, publish about pro-
grams that faced exceptional challenges. Funnel plots of
proportion with tests read of those with tests placed and
proportions with positive tests of those with valid results
for TST studies (Additional file 5) did not reveal any
obvious asymmetry, but funnel plot asymmetry is largely
due to the use of null-hypothesis significance testing.
Because the included studies were not comparative in
nature, there was no significance testing for the individ-
ual study proportions and publication bias may shift the
entire distribution rather than causing asymmetry.
Another consequence of incomplete reporting of tar-
geted testing programs is that it is not possible to know
what proportion of the homeless population is currently
reached by these programs, which in turn makes it diffi-
cult to estimate the possible effects of scaling up testing
in this population.
Misclassification is another potential source of bias;
numbers of persons who were retained at each step of the
cascade may not have been recorded correctly, and mis-
takes may have been made in interpreting test results.
Studies did not generally provide sufficient evidence to
evaluate the risk of bias due to misclassification.
In 2015, 66.4% of reported cases of TB disease in the
United States were in persons who were born in another
country, and TB incidence was nearly 13 times higher in
persons born outside the US than those born in the US.
Per data from the Online Tuberculosis Information
System, 30.5% of recently homeless persons with TB dis-
eases between 2011 and 2015 were also born outside the
US [41]. However, we found very little information in
our included studies regarding the intersection of these
two critical risk populations in our included studies.
Only one study stated the proportion of the study popu-
lation that was born abroad; this study found that 17.3%
of 260 homeless persons tested for TB in Los Angeles in
the early 1990’s were non-US born [16].
There are also issues that limit the generalizability of
our results. We included 17 studies conducted wholly or
in part prior to 2000. The preponderance of older stud-
ies limits generalizability due to possible changes in
LTBI prevalence. While the proportion of reported cases
of TB disease in persons experiencing recent homeless-
ness has remained at about 6% since the mid-1990s, the
number of incident cases of TB disease in the United
States have decreased in both the general public and
homeless populations, with only 495 cases reported in
2015 in persons experiencing homelessness in the last
year vs. 795 cases reported in 2005 [2]. The decline in
cases in persons experiencing homelessness may be par-
tially due to the active case-finding activities that have
been advocated for these populations since the 1990’s
[34]. We also found that studies were mainly conducted
in coastal urban areas, meaning that our results may
generalize poorly to testing programs for homeless
persons in other settings.
Most studies in this review relied on TST, rather than
IGRA for testing [42], and the studies that did use IGRA re-
ported a limited number of cascade steps. In addition, the
two studies that used IGRA exclusively were both con-
ducted in San Francisco, and both recruited from healthcare
facilities, limiting generalizability of results. Given these limi-
tations, we do not think it is appropriate to use the results
of this review to compare relative performance of TST with
IGRA. The two studies which relied exclusively on IGRAs
for testing did not report the number of persons (either
those testing positive or overall) who received their test re-
sults, but in a separate review [unpublished] of targeted
blood-borne infection testing for homeless persons, we esti-
mated that only 57.9% of persons testing positive for HCV
infection and 50.8% of persons testing positive for HIV in-
fection were given test results. Additional studies are needed
to assess LTBI test positivity and referral for follow-up care
using the newer IGRA diagnostics.
Almost all of the studies included in this review
recruited participants from health care facilities, shelters,
or other types of service agencies. Only two [11, 16] in-
cluded persons recruited through outreach or street venue
based sampling. Because some homeless persons cannot
or do not access services, most of the programs we
reviewed likely left a large subpopulation of homeless per-
sons without access to testing. We have conducted some
stratified analyses by the type of service agency where re-
cruitment was done, but failure to find a significant differ-
ence between proportions should be interpreted with
caution because tests for heterogeneity are low-powered
and frequently fail to reject false hypotheses.
We found high heterogeneity in most of our pooled pro-
portions, indicating a high probability that study results
differed from one another due to underlying program fac-
tors, rather than random variability. The random effects
model that we used to calculate pooled proportions expli-
citly allows pooling of results sampled from differing
underlying probability distributions. However, since our
results indicate that real-world performance is likely to
differ substantially between programs, program planners,
modelers, and others who wish to incorporate our results
into their work should consider our confidence intervals,
in addition to our point estimates.
Conclusions
CDC recommends TTT for populations at risk for TB,
which is an important strategy for the United States to
Parriott et al. BMC Public Health  (2018) 18:485 Page 9 of 11
achieve TB elimination. Persons in congregate settings,
including homeless shelters, are among populations at
highest risk for TB transmission and outbreaks. In
addition to identification of previously undiagnosed
cases of TB among persons experiencing homelessness
and prevention of TB outbreaks, TTT contributes to
future TB prevention through treatment of LTBI. The U.
S. Preventive Services Task Force issued a B grade rec-
ommendation that testing for LTBI in persons at in-
creased risk for infection provides moderate benefit [43].
We found that 24.7% of homeless persons with valid
TST results tested positive for TB infection, compared
with estimated LTBI prevalence in the general popula-
tion of 14.4% in 1971-72, 4.3% in 1999-2000, and 4.7%
in 2011-2012 [35, 44]. These results support classifica-
tion of homeless persons as a high risk population for
TB infection. We also found that large proportions of
targeted populations were successfully tested, and that
most persons testing positive were successfully referred
to follow-up care. TTT programs that use IGRAs for
testing and shorter course LTBI treatment regimens may
be promising ways to improve TB prevention among
persons experiencing homelessness [38]. Further re-
search is needed to reflect changes in LTBI prevalence
among homeless persons over time, to evaluate the rela-
tive benefits of screening with TSTs vs IGRAs, and to
synthesize the literature on treatment adherence in per-
sons experiencing homelessness.
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